Verition Fund Management
KALV

Verition Fund Management’s KalVista Pharmaceuticals KALV Stock Holding History

Verition Fund Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$513K Buy
+25,500
New +$411K ﹤0.01% 1580
2024
Q3 		– Sell
-15,113
Closed -$178K – 3363
2024
Q2 		$178K Buy
+15,113
New +$176K ﹤0.01% 2630
2020
Q1 		– Sell
-31,065
Closed -$553K – 837
2019
Q4 		$553K Buy
+31,065
New +$405K 0.01% 635

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Verition Fund Management's KALV Position: Q1 2026 in Review

Verition Fund Management opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 25,500 shares worth $513K. The stake represents ﹤0.01% of the portfolio and ranks #1580 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in KALV as recently as Q2 2024.

Verition Fund Management first reported a position in KALV in Q4 2019 and has held it in 3 quarters since. The position peaked at $553K in Q4 2019. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Verition Fund Management held 25,500 shares of KalVista Pharmaceuticals worth $513K as of Q1 2026.
  • KalVista Pharmaceuticals was a new Verition Fund Management position in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1580 holding.
  • Verition Fund Management first reported a position in KalVista Pharmaceuticals in Q4 2019 and has held it in 3 quarters since.
  • Verition Fund Management's KalVista Pharmaceuticals position peaked at $553K in Q4 2019.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.